Circulating tumor cell profiling for precision oncology

Labib, Mahmoud

doi:10.1002/1878-0261.12901

Cited by 42 publications

(39 citation statements)

References 177 publications

(198 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As so far, the CellSearch platform, a CTCs detection method based on immunological assay with the epithelial cell adhesion molecule (EpCAM), is the only one to date that is approved by FDA for CTC detection in metastatic breast cancer, prostate cancer, and colorectal cancer. 38 In our study, it was the most common method for CTC enumeration in SCLC. We observed that except for pooled data analysis of the association between post-therapy CTCs detected by CellSearch and PFS, higher CTCs count (baseline and after treatment) was significantly correlated with shorter OS/PFS in SCLC.…”

Section: Discussionmentioning

confidence: 82%

“… 1 , 7 Unlike conventional tissue biopsy, CTCs detection is a non-invasive test that can provide a “moving picture” of longitudinal tumor progression and obtain a comprehensive understanding of the heterogeneous tumor cells throughout the body. 8 , 38 As mentioned before, although numerous studies have indicated that higher CTCs levels were correlated with worse prognosis and early disease recurrence among the vast majority of solid tumors, the prognostic value of CTCs in SCLC remains controversial. It could be attributed to the fact that different detection methods, different sampling times, and unstandardized cut-off values were used in previous studies.…”

Section: Discussionmentioning

confidence: 99%

“…Although it has passed more than a decade since FDA approved the clinical application of the CellSearch platform for CTC detection, it has not been widely utilized in clinical practice, especially in recent tumor-resistant studies. 38 This can be explained by the fact that the platform cannot detect mesenchymal CTCs with downregulated EpCAM and/or cytokeratin (CK) expression. Recently, a growing number of studies have emerged to address the above issue by detecting CTCs with different phenotypes, such as proliferating phenotype (CK+/Ki67+), apoptotic phenotype (CK+/M30+), and Epithelial-to-Mesenchymal Transition (EMT; CK+/Vim+ or CK+/TWIST+) phenotype.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Assessment of the Clinical Utility of Circulating Tumor Cells at Different Time Points in Predicting Prognosis of Patients With Small Cell Lung Cancer: A Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

Objectives Numerous studies have elucidated that circulating tumor cells (CTCs) have significant prognostic value in various solid tumors. However, the prognostic value of CTCs in small cell lung cancer (SCLC) remains controversial. The current study was performed to investigate the prognostic significance of different time points of CTCs in SCLC. Methods PubMed, EMBASE, Web of Science, and Cochrane Library databases were retrieved for eligible studies. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated to investigate the association between CTCs level and overall survival (OS) and progression-free survival (PFS) in SCLC. Furthermore, subgroup analyses, sensitivity analysis, Begg’s and Egger’s tests were also conducted. Results Sixteen cohort studies with 1103 participants were eligible for this meta-analysis. Our results revealed that higher pretreatment CTCs level was significantly correlated with worse OS in SCLC no matter CellSearch (HR, 2.95; 95%CI, 1.56-5.58; P = .001) or other methods (HR, 2.37; 95%CI, 1.13-4.99; P = .023) was used to detect CTCs. Higher pretreatment CTCs status detected by CellSearch was associated with shorter PFS (HR, 3.75; 95%CI, 2.52-5.57; P < .001), while there was no significant association when other methods were adopted to CTC detection (HR, 2.04; 95%CI, .73-5.68; P = .172). Likewise, we observed that higher post-therapy CTCs level detected by both CellSearch (HR, 2.99; 95%CI, 1.51-5.93; P = .002) and other methods (HR, 4.79; 95%CI, 2.03-11.32; P < .001) was significantly correlated with decreased OS in SCLC. However, higher post-therapy CTCs count detected by CellSearch was not correlated with worse PFS (HR, 1.80; 95%CI, .83-3.90; P = .135). Sensitivity analysis demonstrated that the pooled data were still stable after eliminating studies one by one. However, significant publication bias was observed between pretreatment CTCs level detected by CellSearch and OS of SCLC. Conclusion Dynamic monitoring of CTCs level could be a non-invasive and effective tool to predict the disease progression and prognosis in patients with SCLC.

show abstract

Section: Discussionmentioning

confidence: 82%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Assessment of the Clinical Utility of Circulating Tumor Cells at Different Time Points in Predicting Prognosis of Patients With Small Cell Lung Cancer: A Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Thereby, by preserving the molecular identity of the main tumor, they allow a range of analyses including DNA, RNA, and protein levels, as well as functional ones. Moreover, they can surrogate the current methods of follow-up of CRC (with images) leading to earlier diagnosis of recurrences and reduce costs [ 27 ].…”

Section: Liquid Biopsy (Lb) and Targeted Approaches For Analysismentioning

confidence: 99%

Personalized Therapy and Liquid Biopsy—A Focus on Colorectal Cancer

Christou

Veyrune

Popeskou

et al. 2021

JPM

View full text Add to dashboard Cite

(1) Background: Resistance mechanisms represent a barrier to anti-cancer therapies. Liquid biopsies would allow obtaining additional information in order to develop targeted therapies to thwart the resistance phenomena but also to follow in time real response to treatment and be able to adapt it the most quickly possible way in case of resistance. (2) Methods: herein we summarize the different liquid biopsies which are currently under research; we then review the literature and focalize on one of their potential roles: the theranostic one and especially in the cases of colorectal cancers. (3) Results: few studies targeting liquid biopsy as a potential tool to adapt cancer treatments are present in the literature and encompass few patients. (4) Conclusions: further research is needed to prove the efficiency of LB. Indeed, it seems a promising tool to guide treatment by targeting actionable mutations with detection of resistant mutations.

show abstract

“…This special issue on current challenges of liquid biopsy research includes seven articles written by experts in this field of research and covers multiple facets of liquid biopsy: a. CTCs -Vasseur et al [30] summarize the evidence that has established CTCs as an independent prognostic factor in several cancer types (clinical validity), in both localized and metastatic settings, with a particular focus on breast cancer, and the published or ongoing phase II-III clinical trials designed to demonstrate the clinical utility of CTCs. Moreover, Labib et al [31] review key technologies used to isolate and analyze CTCs and discuss recent clinical studies that examined CTCs for genomic and proteomic predictors of responsiveness to therapy. Finally, current limitations that still hamper the implementation of CTCs into clinical practice are pointed out.…”

mentioning

confidence: 99%